In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood ...

CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, ...

Many existing blood pressure-lowering drugs work by blocking aldosterone from binding to ... in glomerular filtration rate, a measure of kidney functioning. "It was overall a well-tolerated ...

Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood ...

chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) saw strong trading volume on Wednesday after HC Wainwright ...